Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.
Gurbakhash Kaur, MD, an assistant professor in the Department of Internal Medicine at University of Texas Southwestern Medical Center, discusses the use of bispecific T-cell engagers (BiTEs) as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.
According to Kaur, BiTEs provide an off-the-shelf approach for patients. CAR T cells require lymphodepletion, after which the cells need to be engineered. For patients in crisis, they may not be able to wait for CAR T cells to be manufactured. According to Kaur, both CAR T cells and BiTE therapies will have a major role in the treatment of multiple myeloma.
0:08 | BiTEs, especially with AMG 420, are also BCMA-targeted agents, but that will be an off-the-shelf type of approach, whereas with CAR T cells you need to give lymphodepletion and wait a couple of weeks for the cells to be engineered. Many patients, when they are in crisis and they run out of options, don’t have the time to wait for a CAR T-cell to be manufactured. Both of these therapies, CAR T cells and BiTE therapies, will have a major role to play in multiple myeloma treatment.